These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15736428)

  • 1. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
    Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
    Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
    Matsumura T; Takigawa N; Kiura K; Shibayama T; Chikamori M; Tabata M; Ueoka H; Tanimoto M
    In Vivo; 2005; 19(4):717-21. PubMed ID: 15999539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
    Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
    Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
    Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
    Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
    Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
    Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
    Kimura T
    Osaka City Med J; 2001 Jun; 47(1):33-41. PubMed ID: 11556390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
    Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Matsumura T; Chikamori M; Matsushita A; Kohara H; Harada M
    Anticancer Res; 1999; 19(1A):291-9. PubMed ID: 10226557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
    Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
    Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I targeting agents in small-cell lung cancer.
    Ohe Y; Saijo N
    Curr Oncol Rep; 2001 Mar; 3(2):170-8. PubMed ID: 11177750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
    Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
    Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.